n*s
发帖数: 53 | 1 Gilead's remdesivir shows positive effect in COVID-19 patients
Apr. 10, 2020 3:58 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W.
House, SA News Editor
A cohort analysis of 53 severely ill hospitalized COVID-19 patients who
received Gilead Sciences' (NASDAQ:GILD) antiviral remdesivir on a
compassionate use basis showed a treatment benefit. The data were just
published in the New England Journal of Medicine.
64% (n=34/53) of patients were on mechanical ventilation at baseline,
including four also on extracorporeal membrane oxygenation (blood is
circulated through an artificial lung to oxygenate).
68% of patients receiving remdesivir experienced an improvement in oxygen
support class over median follow-up of 18 days. 57% (n=17/30) of those on
mechanical ventilation were extubated and 47% (25/53) of the total group
were discharged from the hospital.
After 28 days of follow-up, the cumulative incidence of clinical improvement
was 84% (discharge from hospital and/or at least a two-point improvement
from baseline in predefined six-point scale).
The overall mortality rate was 13% (n=7/53), lower than 18% (n=6/34) in a
subgroup of patients on invasive ventilation.
No new safety signals were observed.
Two Phase 3 studies are in process with topline data from one, SIMPLE,
expected this month.
A China-based study in severely ill COVID-19 patients has been terminated
due to low enrollment while another in mild-to-moderately ill patients in
ongoing.
More than 1,800 patients have received remdesivir to date. |
m******c
发帖数: 1202 | |
l*****u
发帖数: 94 | |
N*****d
发帖数: 9872 | |
w**s
发帖数: 1911 | 5 不让国内参加是正确的选择。
国内的行为：
偷偷注册专利，偷偷生产，偷偷使用，就是不提供反馈，有效也会说无效，一切听中共的
.
【在 n*s 的大作中提到】
: Gilead's remdesivir shows positive effect in COVID-19 patients
: Apr. 10, 2020 3:58 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W.
: House, SA News Editor
: A cohort analysis of 53 severely ill hospitalized COVID-19 patients who
: received Gilead Sciences' (NASDAQ:GILD) antiviral remdesivir on a
: compassionate use basis showed a treatment benefit. The data were just
: published in the New England Journal of Medicine.
: 64% (n=34/53) of patients were on mechanical ventilation at baseline,
: including four also on extracorporeal membrane oxygenation (blood is
: circulated through an artificial lung to oxygenate).
|
h****s
发帖数: 16779 | 6 这句：
The overall mortality rate was 13% (n=7/53), lower than 18% (n=6/34) in a
subgroup of patients on invasive ventilation
算了一下，2-sided p-value = 0.5709. 这样的 p-value，只能说这个东西也许有点
用，离药差远了。
通常这样的 results 叫 Negative results。
等着看别的 study 结果吧。 |
h***t
发帖数: 2540 | 7 这点样本和效果差异根本不说明问题。如果真显著有效，早就上HEADLINE了
.
【在 n*s 的大作中提到】
: Gilead's remdesivir shows positive effect in COVID-19 patients
: Apr. 10, 2020 3:58 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W.
: House, SA News Editor
: A cohort analysis of 53 severely ill hospitalized COVID-19 patients who
: received Gilead Sciences' (NASDAQ:GILD) antiviral remdesivir on a
: compassionate use basis showed a treatment benefit. The data were just
: published in the New England Journal of Medicine.
: 64% (n=34/53) of patients were on mechanical ventilation at baseline,
: including four also on extracorporeal membrane oxygenation (blood is
: circulated through an artificial lung to oxygenate).
|
H******1
发帖数: 1 | 8 没看懂，这药以前伊波拉试药的时候是一半死于肝中毒吧，那这次没有？ |
n*s
发帖数: 53 | 9 this is only for mortality, you also need to view the effect for discharge. |
n*s
发帖数: 53 | 10 sorry, computation is wrong, as it did not clearly mentioned the mortality
in treatment group and placebo group. |
|
|
G*****r
发帖数: 462 | |
n*s
发帖数: 53 | 12 read this
'
We recognize the limitations of these compassionate use data from a purely
investigational perspective, while knowing they are of the greatest
significance for the patients whose symptoms improved.
' |
l*****u
发帖数: 94 | 13 他这个是同情用药的观察数据，没有对照组。但是参考其它数据，上了插管的死亡率，
武汉的说法是到这一步基本活不了，纽约的情况是插管
病人80%死亡率，那么他这个插管病人18%的死亡率是非常大的改善了。 |
l*****u
发帖数: 94 | 14 据Gilead CEO，在中国的重症组实验已经由于招募不到病人而停止：“...but we have
been informed that the study in patients with severe symptoms was stopped
due to stalled enrollment".
太TM荒唐了，当时武汉乌泱乌泱的病人，危重症多的是，居然招不到病人。看来在关键
时刻不能指望厉害国。 |
m******c
发帖数: 1202 | 15 那是因为中国国内同时进行了几百个临床试验，国内的拿了funding抢病人当然优先。
have
【在 l*****u 的大作中提到】
: 据Gilead CEO，在中国的重症组实验已经由于招募不到病人而停止：“...but we have
: been informed that the study in patients with severe symptoms was stopped
: due to stalled enrollment".
: 太TM荒唐了，当时武汉乌泱乌泱的病人，危重症多的是，居然招不到病人。看来在关键
: 时刻不能指望厉害国。
|
l*****u
发帖数: 94 | 16 国内那些个“临床试验”很多就是搞笑。什么“气功”，“冥想”，“清肺汤”，连治
疗机理都没有，动物实验，第一期，第二期都没有，直接上临床试验。
【在 m******c 的大作中提到】
: 那是因为中国国内同时进行了几百个临床试验，国内的拿了funding抢病人当然优先。
:
: have
|
l*********s
发帖数: 5409 | |
x*********4
发帖数: 1 | 18 Good news
【在 l*****u 的大作中提到】
: 他这个是同情用药的观察数据，没有对照组。但是参考其它数据，上了插管的死亡率，
: 武汉的说法是到这一步基本活不了，纽约的情况是插管
: 病人80%死亡率，那么他这个插管病人18%的死亡率是非常大的改善了。
|
